ALBANY, New York, Feb. 9, 2015 /PRNewswire/ -- AMRI (NASDAQ:
AMRI) announced today that Jimmy
Wang, Ph.D., fills the newly created position of Chief
Information Officer, effective immediately. He replaces
Carl Neumann, Senior Director,
Information Technology, who retires this month.
In this role, Dr. Wang will manage and oversee major technology
initiatives at AMRI, as well as the day-to-day Information
Technology operations. Among his responsibilities will be to
implement scalable and agile information technology solutions that
align with AMRI's growth objectives and global operations.
"We are pleased to welcome Jimmy to the AMRI team," said
William S. Marth, president and
chief executive officer, AMRI. "As an award-winning industry
professional with a proven track record in delivering complex IT
transformations, we look forward to leveraging his strategic
direction to create a scalable IT infrastructure that will
accommodate growth. We appreciate Carl's many years of dedication
and service with AMRI, and wish him the best in his
retirement."
Dr. Wang brings 25 years of experience managing and deploying
technology innovations to various technology, telecommunications
and global pharmaceutical companies. Most recently he served as
Senior Vice President and Chief Information Officer at OPKO Health
Inc., where he established the company's global IT governance
process and transformed IT into a centralized delivery
organization. Before OPKO Health, Dr. Wang was Senior Vice
President and Chief Information Officer at Vertex Pharmaceuticals
Inc., where he played a major role in managing implementation,
consolidation, and support of Enterprise Operations Support
Systems, as well as led the area of scientific computing to use
technology to support the area of Innovation and Research. Before
Vertex, Dr. Wang was at Teva Pharmaceuticals-America, where he was
Vice President and Chief Information Officer. Dr. Wang
received his Ph.D. in Operations Research from Southern Methodist University in 1990.
About AMRI
Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America,
Europe and Asia, our key business segments include
Discovery and Development Services (DDS), Active Pharmaceutical
Ingredients (API), and Drug Product Manufacturing. Our DDS segment
provides comprehensive services from hit identification to IND,
including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug
metabolism and pharmacokinetics, as well as natural products. API
Manufacturing supports the chemical development and cGMP
manufacture of complex API, including potent, controlled
substances, biologics, peptides, steroids, and cytotoxic compounds.
Drug Product Manufacturing supports drug product development
through commercial scale production of complex liquid-filled and
lyophilized parenteral formulations. For more information about
AMRI, please visit our website at www.amriglobal.com or follow us
on Twitter (@amriglobal).